Skip to main content

Table 2 Comorbidities, comedication, self-reported events and adherence in patients contacted by phone using a follow-up survey

From: Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth

Patient condition

n (%)

Comorbidities

151 (14.22)

 Hypertension

83 (7.82)

 Diabetes

58 (5.46)

 Asthma

8 (0.75)

 HIV

7 (0.66)

 Other disease

22 (2.07)

Concurrent treatments

 

 Dipyrone

222 (20.90)

 Paracetamol

75 (7.06)

 Renin–angiotensin–aldosterone system inhibitors

36 (3.39)

 Orphenadrine

28 (2.54)

 Oral antidiabetics

19 (1.79)

 Ibuprofen

18 (1.69)

 H1-antihistamines

8 (0.75)

 Diuretics

8 (0.75)

 Dimenhydrinate

6 (0.56)

Number of symptoms suggestive of hemolytic anaemia

 

 No symptoms

217 (20.43)

 1–2 Symptoms

481 (45.29)

 3–4 Symptoms

307 (28.91)

 5–6 Symptoms

57 (5.37)

Type of symptom suggestive of hemolytic anaemia

 

 Dark urine

71 (6.69)

 Yellow skin and / or eyes

419 (39.45)

 Fever

190 (17.89)

 Back pain

511 (48.12)

 Dizziness

586 (55.18)

 Shortness of breath

276 (25.99)

Gastrointestinal changes

 

 Stomach ache

463 (43.60)

 Nausea or vomiting

603 (56.78)

 Diarrhea

339 (31.92)

Skin disorders

 

 Itchy or burning skin

287 (27.02)

 Red patches or patches on the skin

74 (6.97)

Psychiatric disorders

 

 Anxious mood

243 (22.88)

 Depression mood

245 (27.07)

 Hallucination, visual

66 (6.21)

 Lack of appetite

753 (70.90)

Neurological disorders

 

 Headache

821 (77.31)

 Agitation and tremors without control

111 (10.08)

Changes in heart rate

 

 Accelerated heartbeat

345 (32.49)

Ototoxicity

 

 Feeling of loss of balance

392 (36.91)

 Ringing in the ear

130 (12.24)

Adherent to treatment

991 (93.31)

  1. CQ: Chloroquine, PQ: primaquine